Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other financing activities: 2012-2025

Historic Other financing activities for Niagen Bioscience (NAGE) over the last 4 years, with Jun 2025 value amounting to $6,000.

  • Niagen Bioscience's Other financing activities was N/A to $6,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $64,000, marking a year-over-year change of. This contributed to the annual value of $52,000 for FY2024, which is 30.67% down from last year.
  • Latest data reveals that Niagen Bioscience reported Other financing activities of $6,000 as of Q2 2025, which was down 0.00% from $6,000 recorded in Q1 2025.
  • Niagen Bioscience's 5-year Other financing activities high stood at $75,000 for Q4 2023, and its period low was $3,000 during Q2 2021.
  • Over the past 3 years, Niagen Bioscience's median Other financing activities value was $11,000 (recorded in 2024), while the average stood at $27,800.
  • Within the past 5 years, the most significant YoY rise in Niagen Bioscience's Other financing activities was 231.58% (2021), while the steepest drop was 80.00% (2021).
  • Over the past 5 years, Niagen Bioscience's Other financing activities (Quarterly) stood at $63,000 in 2021, then dropped by 1.59% to $62,000 in 2022, then increased by 20.97% to $75,000 in 2023, then plummeted by 45.33% to $41,000 in 2024, then plummeted by 45.45% to $6,000 in 2025.
  • Its Other financing activities was $6,000 in Q2 2025, compared to $6,000 in Q1 2025 and $41,000 in Q4 2024.